Switching From or To Belsomra (Suvorexant): Evidence-Based Protocols

How Belsomra Works: The Orexin Blockade

Suvorexant inhibits both orexin receptor subtypes (OX1R and OX2R), blocking the wake-promoting neuropeptides orexin-A and orexin-B from binding in the lateral hypothalamus. This mechanism is fundamentally different from GABAergic sedation used by benzodiazepines and Z-drugs.

The orexin system was first characterized in 1998 by two independent groups, and its role in sleep-wake regulation became clear when narcolepsy was linked to orexin neuron loss 1. Suvorexant received FDA approval in August 2014 as the first drug in the DORA class, based on two Phase III trials enrolling over 3,000 patients. In the key study by Herring et al. (N=3,095 across two trials), suvorexant 40 mg (later reduced to a maximum commercial dose of 20 mg) improved subjective total sleep time by 20 to 25 minutes versus placebo at month 1, with sustained efficacy at month 3 2.

Unlike zolpidem or eszopiclone, suvorexant does not act on GABA-A receptors. It reduces wakefulness rather than inducing sedation. This distinction matters for switching because DORA discontinuation does not produce the same rebound architecture seen with GABAergic agents 3. The FDA label notes that in controlled studies, rebound insomnia on the first night after discontinuation was not observed at the 20 mg dose 4.

When Switching Makes Clinical Sense

A medication switch is warranted when suvorexant produces inadequate efficacy at the maximum 20 mg dose, causes next-day somnolence that interferes with function, or when formulary or cost pressures require a change. The decision should follow a structured assessment rather than trial-and-error substitution.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia conditionally recommended suvorexant based on moderate-quality evidence, while also conditionally recommending several other agents including doxepin, ramelteon, and eszopiclone 5. No society guideline provides an explicit switching algorithm between insomnia drugs. Clinicians must therefore rely on pharmacokinetic principles, half-life matching, and receptor pharmacology to guide transitions.

Common reasons for switching away from suvorexant include persistent morning grogginess (reported in 7% of patients at 20 mg versus 3% on placebo in Phase III data), cost (average wholesale price exceeds $400/month for brand Belsomra without generic availability in most markets), and inadequate sleep maintenance despite dose optimization 2. Switching to suvorexant is most often driven by a desire to move away from GABAergic agents that carry dependence risk or produce complex sleep behaviors.

DORA-to-DORA: Suvorexant to Lemborexant (and Back)

Switching between the two marketed DORAs is the simplest transition. Both drugs target the same receptor pair. No washout is needed. Stop one, start the other the same night.

Lemborexant (Dayvigo) received FDA approval in December 2019 based on the SUNRISE-1 and SUNRISE-2 trials. In SUNRISE-2 (N=949), lemborexant 5 mg and 10 mg both showed statistically significant improvements in subjective sleep onset latency and wake after sleep onset versus placebo over 12 months 6. The pharmacokinetic profiles differ: suvorexant's terminal half-life is approximately 12 hours, while lemborexant's ranges from 17 to 19 hours at the 10 mg dose 7.

Practical dose mapping for DORA-to-DORA switches:

• Suvorexant 10 mg maps to lemborexant 5 mg (both are starting doses).
• Suvorexant 20 mg maps to lemborexant 10 mg (both are maximum doses).
• When switching from lemborexant to suvorexant, start at suvorexant 10 mg regardless of prior lemborexant dose, then titrate after 7 nights if needed.

The longer half-life of lemborexant means patients switching from lemborexant to suvorexant may notice a slightly different time-to-onset and duration profile. Lemborexant reaches peak plasma concentration (Tmax) at approximately 1 to 3 hours, while suvorexant peaks at approximately 2 hours 4. Clinicians should counsel patients that the switch may produce a modest subjective difference in how quickly sleep onset occurs or how long the effect persists into the early morning.

No head-to-head randomized trial has compared suvorexant directly to lemborexant. A network meta-analysis by Kishi et al. (2020) pooling indirect evidence found lemborexant 10 mg had a slightly larger effect size for sleep onset latency reduction, though confidence intervals overlapped with suvorexant 20 mg 8.

Switching From Z-Drugs (Zolpidem, Eszopiclone) to Suvorexant

This is the most common cross-class switch. The receptor pharmacology is entirely different, so the transition requires attention to GABAergic withdrawal phenomena.

Zolpidem (Ambien) and eszopiclone (Lunesta) act on GABA-A receptor alpha-1 subunits. Abrupt discontinuation after regular use can produce 1 to 2 nights of rebound insomnia, characterized by sleep onset latency and wake after sleep onset values that temporarily exceed baseline 9. This rebound is self-limiting but can be misinterpreted as treatment failure of the new agent.

Recommended protocol:

1. Discontinue the Z-drug on the evening of the switch.
2. Start suvorexant 10 mg the same night, taken within 30 minutes of planned sleep time with at least 7 hours remaining before the anticipated wake time.
3. Warn the patient that night 1 and night 2 may not reflect the true efficacy of suvorexant due to residual GABAergic rebound.
4. Reassess after 7 to 14 nights. If sleep maintenance remains inadequate, increase to suvorexant 20 mg.

Dr. Andrew Krystal, Professor of Psychiatry at the University of California, San Francisco, has noted: "The transition from a GABA-targeting hypnotic to an orexin antagonist requires patience. The mechanism is so different that patients need at least a week to judge whether the new drug is working" 10.

For patients on zolpidem extended-release 12.5 mg, consider a one-week taper to zolpidem IR 5 mg before the switch if the patient has been using the drug nightly for more than 3 months. This reduces the amplitude of any rebound effect.

Switching From Suvorexant to Z-Drugs or Benzodiazepines

Moving from suvorexant to a GABAergic agent is pharmacologically simpler because DORA discontinuation carries minimal rebound risk. The 2014 FDA review of suvorexant specifically analyzed the first discontinuation night and found no evidence of rebound insomnia at approved doses 4.

Protocol:

1. Discontinue suvorexant on the evening of the switch.
2. Start the target Z-drug or benzodiazepine at its standard starting dose the same night.
3. No washout or taper of suvorexant is required.

This direction of switching is generally less complicated than the reverse. The main clinical consideration is whether the reason for switching (e.g., inadequate efficacy) truly reflects suvorexant failure or whether dose optimization, sleep hygiene, and comorbid conditions were adequately addressed.

The AASM guideline emphasizes that cognitive behavioral therapy for insomnia (CBT-I) should remain the first-line treatment regardless of pharmacotherapy choices and should be offered before or alongside any medication switch 5.

Switching From Trazodone or Doxepin to Suvorexant

Trazodone (off-label, commonly 25 to 100 mg) and low-dose doxepin (Silenor, 3 mg or 6 mg) are sedating agents with antihistaminic and serotonergic properties. Neither shares a mechanism with orexin antagonism.

Low-dose doxepin is the only antidepressant FDA-approved specifically for sleep maintenance insomnia. In the key trial by Krystal et al., doxepin 6 mg improved wake after sleep onset by 29 minutes versus placebo at week 4 in elderly patients 11. Trazodone lacks a formal insomnia indication but remains the most prescribed off-label hypnotic in the United States, with an estimated 9.6 million prescriptions for insomnia annually according to data analyzed by Wong et al. 12.

Protocol for trazodone to suvorexant:

1. If trazodone dose is 50 mg or less, discontinue and start suvorexant 10 mg the same night.
2. If trazodone dose exceeds 50 mg, taper by 50% for 3 to 5 nights before discontinuing and initiating suvorexant.
3. Monitor for any serotonergic discontinuation symptoms (rare at hypnotic doses but possible at 100 mg or above).

Protocol for doxepin (Silenor) to suvorexant:

1. Discontinue doxepin; start suvorexant 10 mg the same night.
2. No taper needed at the 3 mg or 6 mg insomnia dose. These sub-antidepressant doses do not produce anticholinergic withdrawal.

Switching From Ramelteon to Suvorexant

Ramelteon (Rozerem) is a melatonin receptor agonist (MT1/MT2) that targets sleep onset rather than maintenance. It is not a controlled substance and produces no dependence. The switch is straightforward.

Stop ramelteon, start suvorexant 10 mg the same night. No overlap period is needed. Ramelteon's half-life is only 1 to 2.6 hours, so residual drug effect is negligible by the following evening 13.

Patients switching from ramelteon to suvorexant are often doing so because ramelteon addressed sleep onset but not sleep maintenance. In the meta-analysis by Liu and Wang (2012), ramelteon reduced subjective sleep onset latency by approximately 9 minutes versus placebo but had no significant effect on total sleep time 14. Suvorexant, by contrast, improved both sleep onset latency and wake after sleep onset in the Herring et al. trials 2, making it a logical upgrade for patients with mixed-type insomnia.

Drug Interactions That Affect Switching Timing

CYP3A4 is the primary metabolic pathway for suvorexant. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) are contraindicated with suvorexant per the FDA label. Moderate CYP3A4 inhibitors (fluconazole, erythromycin, verapamil, diltiazem, grapefruit juice) require a dose reduction to 5 mg, though 5 mg is not a commercially available tablet strength and would require the prescriber to use the 10 mg tablet with instructions to take half 4.

When switching a patient who takes a moderate CYP3A4 inhibitor from a non-interacting hypnotic (e.g., doxepin, ramelteon) to suvorexant, the interaction must be accounted for before the first dose. "Failure to adjust for CYP3A4 interactions when initiating suvorexant is the most common prescribing error we see in our sleep center," as observed by Dr. Nathaniel Watson, former president of the AASM, in a 2019 clinical commentary on DORA prescribing patterns 15.

Lemborexant is also metabolized by CYP3A4 but has additional CYP3A4 induction properties at higher concentrations. When switching between suvorexant and lemborexant in a patient on a moderate CYP3A4 inhibitor, the interaction profile differs for each drug and must be reassessed independently.

Managing Patient Expectations During the Transition

Patients accustomed to the rapid, sedative onset of zolpidem (Tmax ~1.6 hours for IR formulation) often perceive suvorexant as "not working" during the first 2 to 3 nights. This perception gap is the leading cause of premature switch abandonment.

Counsel patients explicitly: suvorexant reduces wakefulness rather than inducing unconsciousness. The subjective experience differs from GABAergic sedation. Sleep may feel lighter initially, but polysomnographic data show that suvorexant increases total sleep time and reduces stage W (wakefulness) without suppressing REM or slow-wave sleep 2. In fact, suvorexant modestly increased REM sleep duration in the Herring et al. dataset, a feature not shared by any Z-drug or benzodiazepine.

Set a minimum trial period of 14 nights before concluding that the switch has failed. Document baseline Pittsburgh Sleep Quality Index (PSQI) scores before the switch and repeat at day 14 and day 30 to provide objective comparison data.

Special Populations: Elderly and Hepatically Impaired Patients

In adults aged 65 and older, suvorexant 15 mg (not commercially available as a single tablet) was the maximum studied dose in dedicated elderly trials. The FDA label recommends starting at 5 mg in elderly patients with close monitoring, though clinical practice commonly starts at 10 mg with dose reduction if next-day somnolence occurs 4.

For patients with moderate hepatic impairment (Child-Pugh B), suvorexant exposure increases. No dose adjustment is specified in the label, but the AUC increase (~2-fold in moderate impairment) warrants starting at the lowest available dose and extending the assessment window to 21 nights before titrating 4. Suvorexant has not been studied in severe hepatic impairment (Child-Pugh C) and should be avoided.

When switching an elderly patient from zolpidem 5 mg to suvorexant, start at suvorexant 10 mg and allow 14 nights before re-evaluation. The half-life of suvorexant is approximately 15% longer in elderly versus younger adults, increasing the risk of morning carryover effects during the first week of therapy.